SE9604097L - Inhibitorer av rotamasenzymaktivitet - Google Patents

Inhibitorer av rotamasenzymaktivitet

Info

Publication number
SE9604097L
SE9604097L SE9604097A SE9604097A SE9604097L SE 9604097 L SE9604097 L SE 9604097L SE 9604097 A SE9604097 A SE 9604097A SE 9604097 A SE9604097 A SE 9604097A SE 9604097 L SE9604097 L SE 9604097L
Authority
SE
Sweden
Prior art keywords
enzyme activity
inhibitors
rotamase enzyme
rotamase
fkbp
Prior art date
Application number
SE9604097A
Other languages
English (en)
Swedish (sv)
Other versions
SE9604097D0 (sv
Inventor
Joseph P Steiner
Solomon Snyder
Gregory S Hamilton
Original Assignee
Guilford Pharm Inc
Univ Johns Hopkins Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27044341&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9604097(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/474,072 external-priority patent/US5798355A/en
Application filed by Guilford Pharm Inc, Univ Johns Hopkins Med filed Critical Guilford Pharm Inc
Publication of SE9604097D0 publication Critical patent/SE9604097D0/xx
Publication of SE9604097L publication Critical patent/SE9604097L/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
SE9604097A 1995-06-07 1996-11-08 Inhibitorer av rotamasenzymaktivitet SE9604097L (sv)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/474,072 US5798355A (en) 1995-06-07 1995-06-07 Inhibitors of rotamase enzyme activity
US08/653,905 US5696135A (en) 1995-06-07 1996-05-28 Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
PCT/US1996/009561 WO1996040140A1 (en) 1995-06-07 1996-06-05 Inhibitors of rotamase enzyme activity

Publications (2)

Publication Number Publication Date
SE9604097D0 SE9604097D0 (sv) 1996-11-08
SE9604097L true SE9604097L (sv) 1996-12-08

Family

ID=27044341

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9604097A SE9604097L (sv) 1995-06-07 1996-11-08 Inhibitorer av rotamasenzymaktivitet

Country Status (28)

Country Link
US (5) US5696135A (xx)
EP (1) EP0777478B1 (xx)
AU (1) AU710423B2 (xx)
BG (1) BG102072A (xx)
BR (1) BR9608485A (xx)
CA (1) CA2206824C (xx)
CH (1) CH689541A5 (xx)
CZ (1) CZ232997A3 (xx)
DE (1) DE19680255T1 (xx)
DK (1) DK125696A (xx)
EA (1) EA001379B1 (xx)
EE (1) EE9700331A (xx)
ES (3) ES2166740B1 (xx)
FI (1) FI964137A (xx)
GB (1) GB2305605B (xx)
HK (1) HK1013254A1 (xx)
HU (1) HUP9900816A3 (xx)
LU (1) LU88834A1 (xx)
LV (1) LV11986B (xx)
MX (1) MX9707552A (xx)
NO (1) NO974290L (xx)
NZ (1) NZ310767A (xx)
PL (1) PL323381A1 (xx)
SE (1) SE9604097L (xx)
SI (1) SI9620089A (xx)
SK (1) SK161097A3 (xx)
TW (1) TW523410B (xx)
WO (1) WO1996040140A1 (xx)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2324527B (en) * 1995-06-07 1999-12-22 Guilford Pharm Inc Small molecule inhibitors of rotamase enzyme activity
US7056935B2 (en) * 1995-06-07 2006-06-06 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US5859031A (en) 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US6509477B1 (en) 1998-11-12 2003-01-21 Guilford Pharmaceuticals Inc. Small molecule inhibitors of rotamase enzyme activity
US6291510B1 (en) 1995-06-07 2001-09-18 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US6037370A (en) * 1995-06-08 2000-03-14 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5801197A (en) * 1995-10-31 1998-09-01 Gpi Nil Holdings, Inc. Rotamase enzyme activity inhibitors
US5794887A (en) 1995-11-17 1998-08-18 Komerath; Narayanan M. Stagnation point vortex controller
US5801187A (en) 1996-09-25 1998-09-01 Gpi-Nil Holdings, Inc. Heterocyclic esters and amides
US5840736A (en) * 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5780484A (en) * 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
US5811434A (en) * 1996-11-13 1998-09-22 Vertex Pharmacueticals Incorporated Methods and compositions for stimulating neurite growth
SK57899A3 (en) * 1996-12-31 2000-05-16 Guilford Pharm Inc N-linked ureas and carbamates of heterocyclic thioesters
US5935989A (en) 1996-12-31 1999-08-10 Gpi Nil Holdings Inc. N-linked ureas and carbamates of heterocyclic thioesters
US5874449A (en) * 1996-12-31 1999-02-23 Gpi Nil Holdings, Inc. N-linked sulfonamides of heterocyclic thioesters
US5721256A (en) * 1997-02-12 1998-02-24 Gpi Nil Holdings, Inc. Method of using neurotrophic sulfonamide compounds
US5846979A (en) 1997-02-28 1998-12-08 Gpi Nil Holdings, Inc. N-oxides of heterocyclic esters, amides, thioesters, and ketones
US6852496B1 (en) 1997-08-12 2005-02-08 Oregon Health And Science University Methods of screening for agents that promote nerve cell growth
US6268384B1 (en) 1997-08-29 2001-07-31 Vertex Pharmaceuticals Incorporated Compounds possessing neuronal activity
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
US6121280A (en) * 1998-03-24 2000-09-19 Pfizer Inc. Azabicyclic rotomase inhibitors
WO1999062511A1 (en) * 1998-06-02 1999-12-09 Bristol-Myers Squibb Company Neurotrophic difluoroamide agents
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
AU1708099A (en) * 1998-06-03 1999-12-20 Amgen, Inc. N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres
GEP20043368B (en) 1998-07-17 2004-04-13 Agouron Pharma Compounds, Compositions, and Methods For Stimulating Neuronal Growth and Elongation
GB9815880D0 (en) * 1998-07-21 1998-09-16 Pfizer Ltd Heterocycles
US6333340B1 (en) * 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6335348B1 (en) * 1998-08-14 2002-01-01 Gpi Nil Holdings, Inc. Nitrogen-containing linear and azepinyl/ compositions and uses for vision and memory disorders
US6376517B1 (en) * 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
EP1105112A2 (en) * 1998-08-14 2001-06-13 GPI NIL Holdings, Inc. Compositions and uses for vision and memory disorders
US7338976B1 (en) * 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US7265150B1 (en) * 1998-08-14 2007-09-04 Gpi Nil Holdings Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
US6462072B1 (en) 1998-09-21 2002-10-08 Gpi Nil Holdings, Inc. Cyclic ester or amide derivatives
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
US6228872B1 (en) 1998-11-12 2001-05-08 Bristol-Myers Squibb Company Neurotrophic diamide and carbamate agents
AU3221300A (en) * 1999-02-03 2000-08-25 Schering Aktiengesellschaft Carboxylic acid derivatives, process for their preparation and their use as rotamase enzyme activity inhibitors
US6284779B1 (en) 1999-02-03 2001-09-04 Schering Aktiiengesellschaft Heteroaromatic compounds
EP1196386A2 (en) 1999-07-06 2002-04-17 Vertex Pharmaceuticals Incorporated N-substituted glycine derivatives
BR0012327A (pt) 1999-07-09 2002-07-02 Ortho Mcneil Pharm Inc Pirrolidinas e piperidinas neurotróficas, e composições e métodos relacionados
AU5606400A (en) 1999-07-09 2001-01-30 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic tetrahydroisoquinolines and tetrahydrothienopyridines, and related compositions and methods
US6544976B1 (en) 1999-07-09 2003-04-08 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
US6734211B1 (en) 1999-07-09 2004-05-11 Oregon Health & Sciences University Compositions and methods for promoting nerve regeneration
WO2001012622A1 (en) * 1999-08-18 2001-02-22 Schering Aktiengesellschaft Piperidine and pyrrolidine derivatives displaying neuronal activity
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
EP1214293A1 (en) 1999-09-08 2002-06-19 Guilford Pharmaceuticals Inc. Non-peptidic cyclophilin binding compounds and their use
AU784347B2 (en) * 1999-11-12 2006-03-16 Alcon Inc. Neurophilin ligands for treating ocular conditions
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
GT200000203A (es) 1999-12-01 2002-05-24 Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas.
US6818643B1 (en) 1999-12-08 2004-11-16 Bristol-Myers Squibb Company Neurotrophic bicyclic diamides
AU1464101A (en) 1999-12-21 2001-07-03 Gpi Nil Holdings, Inc. Hydantoin derivative compounds, pharmaceutical compositions, and methods of using same
US6656971B2 (en) 2001-01-25 2003-12-02 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
US7041283B1 (en) 2001-02-16 2006-05-09 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods of using immunophilin binding drugs to improve integration and survival of neuronal cell transplants
US6593362B2 (en) 2001-05-21 2003-07-15 Guilford Pharmaceuticals Inc. Non-peptidic cyclophilin binding compounds and their use
US20030203890A1 (en) * 2001-05-29 2003-10-30 Steiner Joseph P. Method for treating nerve injury caused as a result of surgery
ATE421525T1 (de) * 2001-08-20 2009-02-15 Max Planck Gesellschaft Katalyse der cis-trans isomerisierung von sekundären-amid peptidverbindungen
CN1173960C (zh) 2001-12-06 2004-11-03 中国人民解放军军事医学科学院毒物药物研究所 取代六元氮杂环类化合物及其作为神经调节剂的用途
US20030176455A1 (en) * 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
EP1402888A1 (en) * 2002-09-18 2004-03-31 Jerini AG The use of substituted carbocyclic compounds as rotamases inhibitors
US20050282865A1 (en) * 2002-10-15 2005-12-22 Fujisawa Pharmaceutical Co., Ltd. Neurotrophic factor production promoter
US7033612B2 (en) * 2003-01-03 2006-04-25 Kang David S Composition and method for treating age-related disorders
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
WO2005027906A1 (en) 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
CN1934117A (zh) * 2004-03-02 2007-03-21 惠氏公司 大环内酯及其生产方法
JP2007526312A (ja) * 2004-03-02 2007-09-13 ワイス 神経保護および／または神経再生剤としての非免疫抑制性イムノフィリンリガンド
AU2005252673A1 (en) * 2004-06-03 2005-12-22 Wyeth Biosynthetic gene cluster for the production of a complex polyketide
US7777042B2 (en) * 2004-06-29 2010-08-17 Aventis Pharmaceuticals Inc. N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof
ATE546430T1 (de) * 2004-06-29 2012-03-15 Aventis Pharma Inc Fkbp bindende zusammensetzung und deren pharmazeutische verwendung
US20060189551A1 (en) * 2004-10-04 2006-08-24 Duke University Combination therapies for fungal pathogens
US7276498B2 (en) * 2004-12-20 2007-10-02 Wyeth Rapamycin analogues and uses thereof in the treatment of neurological disorders
RU2007119585A (ru) 2004-12-20 2009-01-27 Вайет (Us) Производные рапамицина и их применение при лечении неврологических заболеваний
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
KR20070104931A (ko) 2005-02-09 2007-10-29 마커사이트, 인코포레이티드 안구 치료용 제제
JP2008539276A (ja) * 2005-04-27 2008-11-13 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド ヒト疾患に関連する変異体タンパク質の分解能を改善するための材料及び方法
JP2008545663A (ja) * 2005-05-27 2008-12-18 クイーンズ ユニバーシティ アット キングストン タンパク質フォールディング障害の治療
CA2635797C (en) 2006-02-09 2015-03-31 Macusight, Inc. Stable formulations, and methods of their preparation and use
DK2001466T3 (en) 2006-03-23 2016-02-29 Santen Pharmaceutical Co Ltd LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES
CA2709566A1 (en) * 2007-12-17 2009-06-25 Gliamed, Inc. Stem-like cells and method for reprogramming adult mammalian somatic cells
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
US20100317711A1 (en) * 2008-12-17 2010-12-16 Gliamed, Inc. Stem-like cells and method for reprogramming adult mammalian somatic cells
EP2705856A1 (en) 2012-09-07 2014-03-12 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. Compounds for the treatment of neurodegenerative disorders
US9121859B2 (en) 2012-12-04 2015-09-01 Siemens Healthcare Diagnostics Inc. Compounds and methods for determination of FKBP-binding immunosuppressant drugs
EP2970426B1 (en) 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
TWI750110B (zh) 2014-07-21 2021-12-21 瑞士商諾華公司 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
AU2015317608B2 (en) 2014-09-17 2021-03-11 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
US11066416B2 (en) 2016-02-04 2021-07-20 The Johns Hopkins University Rapafucin derivative compounds and methods of use thereof
EP3782636B1 (en) 2016-02-04 2024-05-15 The Johns Hopkins University Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof
US11708391B2 (en) 2016-02-04 2023-07-25 The Johns Hopkins University Rapaglutins, novel inhibitors of GLUT and use thereof
CN108713028B (zh) * 2016-02-04 2021-12-28 约翰霍普金斯大学 rapafucin文库的合成和组合物
KR20210020932A (ko) 2018-06-13 2021-02-24 노파르티스 아게 Bcma 키메라 항원 수용체 및 이의 용도
CN114533708A (zh) * 2022-03-23 2022-05-27 四川大学 Boropinol-B在制备治疗脑卒中药物中的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578474A (en) * 1980-06-23 1986-03-25 E. R. Squibb & Sons, Inc. Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids
US4390695A (en) * 1980-06-23 1983-06-28 E. R. Squibb & Sons, Inc. Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids
US4310461A (en) * 1980-06-23 1982-01-12 E. R. Squibb & Sons, Inc. Imido, amido and amino derivatives of mercaptoacyl prolines and pipecolic acids
US4531964A (en) * 1982-09-13 1985-07-30 Nippon Kayaku Kabushiki Kaisha Heterocyclic compound and a herbicidal composition containing said compound
US4593102A (en) * 1984-04-10 1986-06-03 A. H. Robins Company, Inc. N-[(amino)alkyl]-1-pyrrolidine, 1-piperidine and 1-homopiperidinecarboxamides (and thiocarboxamides) with sulfur linked substitution in the 2, 3 or 4-position
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5242932A (en) * 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
US5504197A (en) * 1990-06-20 1996-04-02 The Salk Institute For Biological Studies DNA encoding neurotrophic growth factors
US5192773A (en) * 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
WO1992004370A1 (en) * 1990-08-29 1992-03-19 Vertex Pharmaceuticals Incorporated Modified di- and tripeptidyl immunosuppressive compounds
WO1992016501A1 (en) * 1991-03-20 1992-10-01 Vertex Pharmaceuticals Incorporated Tetrahydroxyalkane derivatives as inhibitors of hiv aspartyl protease
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
WO1992019745A1 (en) * 1991-05-08 1992-11-12 Vertex Pharmaceuticals Incorporated Rfkbp: a novel prolyl isomerase and rapamycin/fk506 binding protein
AU1995792A (en) * 1991-05-09 1992-12-21 Vertex Pharmaceuticals Incorporated Novel immunosuppressive compounds
US5620971A (en) * 1991-05-09 1997-04-15 Vertex Pharmaceuticals Incorporated Biologically active acylated amino acid derivatives
MX9202466A (es) * 1991-05-24 1994-06-30 Vertex Pharma Compuestos inmunosupresores novedosos.
AU2803692A (en) * 1991-10-11 1993-05-03 Vertex Pharmaceuticals Incorporated Isolation of an mr 52,000 fk506 binding protein and molecular cloning of a corresponding human cdna
CA2091194A1 (en) * 1992-04-08 1993-10-09 Richard D. Connell 2-oxo-ethyl derivatives as immunosuppressants
AU4388893A (en) * 1992-05-20 1993-12-13 Vertex Pharmaceuticals Incorporated Method of detecting tissue-specific FK506 binding protein messenger RNAs and uses thereof
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
NZ314207A (en) * 1992-09-28 2000-12-22 Vertex Pharma 1-(2-Oxoacetyl)-piperidine-2-carboxylic acid derivatives as multi drug resistant cancer cell sensitizers
AU5748194A (en) * 1992-12-11 1994-07-04 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease
DE4302860A1 (de) * 1993-01-22 1994-08-04 Chemie Linz Deutschland N-Cyclische und N,N'dicyclische Harnstoffe
US5385918A (en) * 1993-02-09 1995-01-31 Miles Inc. Aminomethylene-peptides as immunosuppressants
US5846981A (en) * 1993-05-28 1998-12-08 Gpi Nil Holdings Inc. Inhibitors of rotamase enzyme activity
US5798355A (en) * 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
GB2279006A (en) * 1993-06-03 1994-12-21 Fujisawa Pharmaceutical Co Treatment of amyotrophic lateral sclerosis
AU699483B2 (en) * 1994-03-07 1998-12-03 Vertex Pharmaceuticals Incorporated Sulphonamide derivatives as aspartyl protease inhibitors
US5744485A (en) * 1994-03-25 1998-04-28 Vertex Pharmaceuticals Incorporated Carbamates and ureas as modifiers of multi-drug resistance
US5898029A (en) * 1994-04-12 1999-04-27 The John Hopkins University Direct influences on nerve growth of agents that interact with immunophilins in combination with neurotrophic factors
US6057119A (en) * 1994-06-17 2000-05-02 Vertex Pharmaceuticals, Incorporated Crystal structure and mutants of interleukin-1β converting enzyme
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5488816A (en) * 1994-07-21 1996-02-06 Boehringer Mannheim Corporation Method and apparatus for manufacturing a coagulation assay device in a continuous manner
US5543423A (en) * 1994-11-16 1996-08-06 Vertex Pharmaceuticals, Incorporated Amino acid derivatives with improved multi-drug resistance activity
IL115685A (en) * 1994-11-16 2000-08-31 Vertex Pharma Amino acid derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
SI9500173B (sl) 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
US5726184A (en) * 1995-05-19 1998-03-10 Vertex Pharmaceuticals Incorporated Tetralin compounds with improved MDR activity
US5859031A (en) * 1995-06-07 1999-01-12 Gpi Nil Holdings, Inc. Small molecule inhibitors of rotamase enzyme activity
US5696135A (en) * 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
US6037370A (en) * 1995-06-08 2000-03-14 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth

Also Published As

Publication number Publication date
HUP9900816A2 (hu) 1999-07-28
GB2305605B (en) 2000-01-12
HK1013254A1 (en) 1999-08-20
SE9604097D0 (sv) 1996-11-08
CH689541A5 (de) 1999-06-15
US5696135A (en) 1997-12-09
AU710423B2 (en) 1999-09-23
MX9707552A (es) 1998-07-31
ES2138518B1 (es) 2001-01-01
NO974290D0 (no) 1997-09-17
EP0777478A4 (en) 1998-07-08
EP0777478B1 (en) 2001-11-07
DK125696A (da) 1996-12-20
GB2305605A8 (en) 1999-01-20
EA199700360A1 (ru) 1998-08-27
BG102072A (en) 1998-08-31
PL323381A1 (en) 1998-03-30
ES2166740B1 (es) 2003-11-01
WO1996040140A1 (en) 1996-12-19
ES2194596B1 (es) 2005-02-16
ES2138518A1 (es) 2000-01-01
AU6162296A (en) 1996-12-30
FI964137A0 (fi) 1996-10-15
CA2206824C (en) 2001-08-14
GB2305605A (en) 1997-04-16
GB9624258D0 (en) 1997-01-08
US20020052372A1 (en) 2002-05-02
ES2194596A1 (es) 2003-11-16
US5843960A (en) 1998-12-01
US20030114365A1 (en) 2003-06-19
SI9620089A (sl) 1999-04-30
SK161097A3 (en) 1998-11-04
HUP9900816A3 (en) 2000-02-28
NO974290L (no) 1997-12-04
US6500843B2 (en) 2002-12-31
DE19680255T1 (de) 1997-06-05
LU88834A1 (de) 1997-01-15
CA2206824A1 (en) 1996-12-19
LV11986A (lv) 1998-03-20
ES2166740A1 (es) 2002-04-16
US6022878A (en) 2000-02-08
CZ232997A3 (cs) 1998-07-15
EE9700331A (et) 1998-06-15
EA001379B1 (ru) 2001-02-26
TW523410B (en) 2003-03-11
FI964137A (fi) 1997-01-15
NZ310767A (en) 2000-11-24
LV11986B (en) 1998-09-20
BR9608485A (pt) 1999-07-06
EP0777478A1 (en) 1997-06-11

Similar Documents

Publication Publication Date Title
SE9604097D0 (sv) Inhibitorer av rotamasenzymaktivitet
NO981903L (no) SmÕ-molekylµre inhibitorer for rotamase enzymaktivitet
NZ507720A (en) Effecting neuronal activity with heterocyclic thioesters and ketones
ES2131457A1 (es) Pequeños inhibidores de moleculas de la actividad de enzimas de rotamasa.
NO982264D0 (no) Inhibitorer av cyklofilinrotamaseaktivitet
NO991433L (no) Heterosykliske estere og amider
MXPA99006120A (es) Sulfonamidas n-enlazadas de tioesteres heterociclicos.
TR200001644T2 (tr) Rotamaz enzim aktivtesinin küçük molekülle inhibitörleri
NZ508838A (en) Heterocyclic compounds as inhibitors of rotamase enzymes
NO992268L (no) N-bundne sulfonamider av heterocykliske tioestere
BR0210060A (pt) Ligandos de fkbp de heterobiciclos
AR004113A1 (es) Inhibidores de actividad de enzima rotamasa.
ES2170628A1 (es) Pequeños inhibidores de moleculas de la actividad de enzimas de rotamasa
TR199801226A2 (xx) Rotamaz enzim etkinliği inhibitörleri.
NO20010191L (no) Forbindelser, materialer og fremgangsmÕter for Õ stimulere neuronal vekst og elongering

Legal Events

Date Code Title Description
NAV Patent application has lapsed